GlassScriptPhysician profile
Mark Joseph Yurchisin
NPI 1568439529
$48,027.79
in general payments reported to CMS, 2019-2025
31 companies · $12K in 2025
The $12K reported for 2025 was more than what 96% of Gynecology providers received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,320 · 2020: $564 · 2021: $2,151 · 2023: $18K · 2024: $13K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $44K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $43,992.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kedplasma LLC | $43,992.46 | 2023-2025 | |
| Abbvie INC. | $922.80 | 2019-2021 | |
| Amgen INC. | $743.03 | 2019-2021 | |
| Aspira Women'S Health INC | $517.31 | 2021 | |
| Astellas Pharma US INC | $348.05 | 2019-2021 | |
| Daiichi Sankyo INC. | $278.28 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $171.13 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $142.37 | 2021 | |
| Allergan, INC. | $124.31 | 2019 | |
| Lilly USA, LLC | $106.07 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $78.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $69.81 | 2019-2021 | |
| Dysis Medical, INC. | $69.00 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.75 | 2019-2020 | |
| Novo Nordisk INC | $45.66 | 2019-2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $45.11 | 2019 | |
| Agile Therapeutics, INC. | $31.98 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.71 | 2019 | |
| Hologic Sales and Service, LLC | $30.60 | 2021 | |
| Lupin INC. | $26.29 | 2019-2020 | |
| Becton, Dickinson and Company | $25.89 | 2019-2021 | |
| Medtronic, INC. | $23.67 | 2021 | |
| Evofem Biosciences, INC. | $23.54 | 2020-2021 | |
| Mayne Pharma Commercial LLC | $22.16 | 2021 | |
| Medtronic USA, INC. | $17.21 | 2019 | |
| Karl Storz Endoscopy-America | $17.21 | 2021 | |
| Axonics, INC. | $15.55 | 2021 | |
| Therapeuticsmd, INC. | $14.93 | 2019 | |
| Nevro Corp. | $14.92 | 2019 | |
| Exeltis, USA INC. | $14.03 | 2021 | |
| Eisai INC. | $11.36 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Yurchisin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.